News

Snoretox to Present at Leading Global Veterinary Conferences in 2026

by

Snoretox has been selected to present our recently published research at two of the world’s most prestigious veterinary conferences: the ACVIM Forum (Seattle, June 2026) and the ECVS Annual Scientific Meeting (Liverpool, July 2026).

These internationally recognised meetings bring together leading veterinary specialists and represent the highest standards of clinical and scientific excellence. Acceptance is competitive and reflects the quality and growing relevance of Snoretox’s work. Presenting at both forums marks an important milestone for the company and highlights its increasing recognition within the global veterinary community.

‘The Veterinary Journal’ publishes our ground breaking research.

by

Clinical observations of tetanus toxin plus decoy, Snoretox-1, a novel targeted stimulant, in a pilot study of 6 British Bulldogs with BOAS’
Anthony Sasse, Luke J. Norbury, Thomas McLean, Maurice Newport, Arthur House, David W. Swift, Danny Aliano, Peter M. Smooker, Russell Conduit.

Click here to read the full article.

Click here to download the full article.

Click here to see the dog video results.

Spontaneous media reporting of one of our trial participants: Courtesy of the Herald Sun Article by Anna Shreeves (photo by Jason Edwards)

by

Breathing easier? Snore thing!

You’ve heard of Botox but it’s time to be introduced to Snoretox, a potentially life-changing drug for dogs that struggle to breathe properly.

This seven-year-old pug, Pugtato, has brachycephalic obstructive airway syndrome, an affliction that often affects the breed.

For many of these flat-faced dogs, there has been no way to remedy their breathing, until now.

A clinical trial led by Dr Arthur House at Peninsula Vet Emergency & Referral Hospital with RMIT University chose Pugtato as its test subject.

Following some preliminary tests, the pug received two injections of Snoretox. Two months on, the effects are said to be remarkable.

Joanna Herceg, Pugtato’s owner and founder of Pug Rescue Victoria, said his improvement had been “overwhelmingly drastic.”

Before Snoretox, he was an “agitated” dog that would struggle to settle. Now, she can barely recognise him. His energy has increased, he is breathing well and he seems like an all-round contented dog.

“I will try to do everything for these dogs, and it’s heartbreaking to watch them suffer from not being able to breathe properly,” Ms Herceg said.

“He has gone from an unadoptable dog to a really awesome adoptable dog.”

pugrescue.org.au

Snoretox Wins the 2025 Innovation Award at the Animal Health Summit in Kansas City

by

Snoretox has won the Emerging Companies Competition at the Animal Health Summit in Kansas City. This summit is the leading deal-making event for veterinary pharmaceutical companies in the USA. The judges selected us unanimously (6 out of 6). We continue to attract a high level of interest, and new opportunities are opening up. This award has both supported this momentum and added value to our company.

Selected to present at KC Animal Health Summit August 2025

by

Snoretox is excited to be selected to participate in the Emerging Company Presentations at the KC Animal Health Summit August 2025

Kansas City is home to the Animal Health Corridor. Because of its significant animal health industry concentration, the Corridor offers a uniquely supportive environment for early-stage entrepreneurs in the animal health, nutrition, diagnostic and technology industry.

14 applicants were selected across all areas from 43 applicants.

https://kcanimalhealth.thinkkc.com/events/animal-health-summit

Selected as Innovation Showcase Finalists 2025

by

We're Finalists in 2025!

The annual Animal Health, Nutrition and Technology Innovation event is the global premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition. It connects those businesses with financial investors and strategic corporate partners.

Competition for selection as a Showcase finalist is intense. There were 8 international selection committee members who have an extensive breadth of experience and knowledge across animal health and nutrition industries.

After a 5-minute presentation, the audience will select a winner.

Selection as a Showcase Finalist alone is significant recognition by experts in the field of the potential of Snoretox products for the treatment of BOAS and other conditions in the Veterinarian sector.

Selected as Finalist Animal Health, Nutrition and Technology Innovation Europe 2025

Snoretox Ltd is excited to be declared an Innovation Showcase Finalist in the Companion Animal section at the Animal Health, Nutrition and Technology Innovation Europe 2025 Convention, 10-12 February 2025 in London, UK, @AHInnovation #AHTNI

Premier singles out Snoretox in Breakthrough Victoria Funding Announcement

by

June 2022.

Snoretox was today singled out in the announcement by Premier Dan Andrews and Treasurer Tim Pallas of $100 million for the Breakthrough Victoria – University Innovation Platform. 

Snoretox is another example of a company commercialising RMIT-developed technology – a novel muscle toning toxin-based therapeutic for treating sleep apnea and snoring, as well as a range of other weak muscle conditions such as incontinence.

Department of Premier and Cabinet

Breakthrough Victoria is backing great ideas that will save lives, change the way we live and provide jobs for the generations that will follow us.

Daniel Andrews

Read the full media release here

More

Snoretox wins prestigious grant

by

The Minister for Health has announced that Snoretox has won a Medical Research Future Fund (MRFF) 2021 Frontier Health and Medical Research Initiative Grant, securing a 1 Million dollar grant.

The MRFF is a 20 Billion dollar fund set up by the Australian Federal Government to promote medical research and it’s translation to the clinic. It’s Frontier Fund is designed to assist BioTech companies to take their products to the market by overcoming financial barriers.

Snoretox wishes to thank RMIT University for it’s important assistance in winning this grant.

Snoretox also wishes to thank it’s collaborative partners: Venture Technology Group, Treidlia BioVet, Accelagen Consultants, Schafer Veterinary Consultants, and Mills Oakley Law Firm.

Snoretox Awarded “Barrier to Innovation” Waiver by the FDA CVM (USA Federal Drug Agency).

by

Innovative Australian Drug receives Break-through Therapy “Barrier to Innovation” Waiver by the FDA CVM  (USA Federal Drug Agency).

The FDA CVM is the FDA’s veterinarian department.

The assessment criteria are

  • Innovation: a drug must be highly innovative, novel, a medical break-through.
  • Efficacy: Is there sufficient information for proof of concept in a validated in vitro system or in the target animal or an animal model of the target animal (e.g., laboratory rodent species)?
  • Small-Medium Company: Is the company below $20 million in market size.

 

We were able to satisfy the criteria and examiners with a detailed application outlining the scientific evidence, they do not give these out lightly.

This success adds serious credibility to our dealings with the government, regulators and the market.

I would like to thank our USA FDA CVM Consultants Schafer and Associates for all their assistance and guidance to date.

a/Prof Anthony Sasse,

What others are saying

Help us help BOAS dogs

We’ll send you news and ways to be involved in giving BOAS dogs a better life.